Lataa...
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their direct effects on crucial survival pathways in malignant B cells. However, these therapies also have effects on T c...
Tallennettuna:
| Julkaisussa: | Blood Adv |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728096/ https://ncbi.nlm.nih.gov/pubmed/29296833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006809 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|